As most readers are probably aware, Mayo Clinic obtained the forst homebrew-approval for BioPorto’s NGAL ELISA kit in the US.

The approval was later redrawn as part of the ongoing discussions with the FDA (Food & Drug Agency ) regarding the automated test The NGAL Test.

I think its fair to say that Mayo Clinic is a world leader in research on AKI and other renal related injuries.

Today they released another study on the relationship between bariatric surgery and AKI

The number of patients developing AKI at the Mayo Clinic is interesting compared to thes reecnt study from Bangladesh

Anyways – for the NGAL afficionados there is not much to find in the article – proably because measurements began as early as 2005…



About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.